Prenatal methotrexate exposure decreases seizure susceptibility in young rats of two strains

Epileptic spasms in infancy: Transferring rat prenatal betamethasone-postnatal NMDA model to mice

Epileptic spasms during infancy represent a devastating and refractory epilepsy syndrome. To advance studies on mechanisms and treatment using available mouse mutant models, we transferred our validated rat model of epileptic spasms to mice. Initially, we determined sensitivity of C57BL/6J mice to various doses (12-20 mg/kg) of NMDA on postnatal day 11 (P11) and P15. We primed mice with different doses of betamethasone (0.4-2.0 mg/kg) prenatally on gestational day (G)14 or G12 and tested spasms on P11. We also tested 2 different ACTH treatment paradigms (0.3 or 1.0 mg/kg) in prenatally primed as well as naïve mice. Data show that spasms in P11 mice, can be induced with the highest yield after 12 mg/kg dose of NMDA. Prenatal priming on G14 did not modify response to NMDA or sensitize spasms to ACTH. The betamethasone priming on G12 resulted in an increase in the number of NMDA-triggered spasms. Data indicate that the model transfer from rats to mice is non-linear and differences in prenatal brain development, metabolic rates, as well as sensitivity to convulsant drugs have to be considered.

Modeling epileptic spasms during infancy: Are we heading for the treatment yet?

Infantile spasms (IS or epileptic spasms during infancy) were first described by Dr. William James West (aka West syndrome) in his own son in 1841. While rare by definition (occurring in 1 per 3200-3400 live births), IS represent a major social and treatment burden. The etiology of IS varies - there are many (>200) different known pathologies resulting in IS and still in about one third of cases there is no obvious reason. With the advancement of genetic analysis, role of certain genes (such as ARX or CDKL5 and others) in IS appears to be important. Current treatment strategies with incomplete efficacy and serious potential adverse effects include adrenocorticotropin (ACTH), corticosteroids (prednisone, prednisolone) and vigabatrin, more recently also a combination of hormones and vigabatrin. Second line treatments include pyridoxine (vitamin B6) and ketogenic diet. Additional treatment approaches use rapamycin, cannabidiol, valproic acid and other anti-seizure medications. Efficacy of these second line medications is variable but usually inferior to hormonal treatments and vigabatrin. Thus, new and effective models of this devastating condition are required for the search of additional treatment options as well as for better understanding the mechanisms of IS. Currently, eight models of IS are reviewed along with the ideas and mechanisms behind these models, drugs tested using the models and their efficacy and usefulness. Etiological variety of IS is somewhat reflected in the variety of the models. However, it seems that for finding precise personalized approaches, this variety is necessary as there is no "one-size-fits-all" approach possible for both IS in particular and epilepsy in general.

Expanding the test set: Chemicals with potential to disrupt mammalian brain development

High-throughput test methods including molecular, cellular, and alternative species-based assays that examine critical events of normal brain development are being developed for detection of developmental neurotoxicants. As new assays are developed, a "training set" of chemicals is used to evaluate the relevance of individual assays for specific endpoints. Different training sets are necessary for each assay that would comprise a developmental neurotoxicity test battery. In contrast, evaluation of the predictive ability of a comprehensive test battery requires a set of chemicals that have been shown to alter brain development after in vivo exposure ("test set"). Because only a small number of substances have been well documented to alter human neurodevelopment, we have proposed an expanded test set that includes chemicals demonstrated to adversely affect neurodevelopment in animals. To compile a list of potential developmental neurotoxicants, a literature review of compounds that have been examined for effects on the developing nervous system was conducted. The search was limited to mammalian studies published in the peer-reviewed literature and regulatory studies submitted to the U.S. EPA. The definition of developmental neurotoxicity encompassed changes in behavior, brain morphology, and neurochemistry after gestational or lactational exposure. Reports that indicated developmental neurotoxicity was observed only at doses that resulted in significant maternal toxicity or were lethal to the fetus or offspring were not considered. As a basic indication of reproducibility, we only included a chemical if data on its developmental neurotoxicity were available from more than one laboratory (defined as studies originating from laboratories with a different senior investigator). Evidence from human studies was included when available. Approximately 100 developmental neurotoxicity test set chemicals were identified, with 22% having evidence in humans.

CNS Aspects of Prenatal Drug Exposure: Drugs of Abuse, Toxins, and Corticosteroids

Studies of the effects of prenatal exposure (to drugs or environmental factors) on postnatal brain morphology and function have an important role in assessing adverse effects of prenatal administration of corticosteroids in obstetrics, in studying the impairment of the offspring due to maternal drug abuse, as well as in studies of the influence of other environmental factors (such as toxins or stress). Timing, duration, and dose of the prenatal exposure play a significant role in the postnatal expression of the impact. However, data interpretation may be complicated by additional factors. As mixed litters of prenatally exposed subjects are evaluated, significant differences between males and females may occur. Additionally in females, cyclical changes in ovarian steroids may interfere with the effects of prenatal impact. Developmental differences may be also present, and data from infant, juvenile, prepubertal, and adult individuals cannot be simply compared. Finally, prenatal treatment is a stressful event and may present itself as prenatal stress, misguiding the interpretation. Postnatal environmental factors in raising the offspring, such as housing, maternal care, light-dark cycle, and weaning age can also change the data in such a way, which makes comparisons between different research laboratories impossible.

Long-term changes in postnatal susceptibility to pilocarpine-induced seizures in rats exposed to gamma radiation at different stages of prenatal development

PURPOSE

To determine whether brains irradiated at different stages of prenatal development also have different postnatal susceptibility to seizures evoked by pilocarpine.

METHODS

Pregnant Wistar rats were exposed to a single 1.0-Gy dose of gamma rays on gestation days 13, 15, 17, or 19 (E13, E15, E17, and E19, respectively). On postnatal day 60, their offspring received i.p. pilocarpine injections to evoke status epilepticus. Behavior of the animals was observed continuously for 6 h after the injection, and motor manifestations of seizure activity were rated, and survival times recorded. After 7-day survival, the animals were killed, and their brains were weighed.

RESULTS

The average brain weight of animals exposed to irradiation at earlier prenatal stages (E13 or E15) was significantly lower than that after irradiation on E17 or E19. However, effects of the irradiation on the susceptibility to pilocarpine-induced seizures were quite opposite. The intensity of status epilepticus evoked in rats irradiated on E13 or E15 was significantly lower than that in nonirradiated controls or in those irradiated on E17 or E19. Moreover, after irradiation on E13 or E15, survival of the animals was significantly higher in relation not only to other irradiated groups but also to the controls.

CONCLUSIONS

The results suggest than the extent of neuronal deficit, even if relatively greater, cannot always lead to higher susceptibility of the dysplastic brain to seizures. Functional consequences of the deficit, even if its magnitude is relatively smaller but involving specific brain areas, appear to be critical for the epileptogenesis.

Prenatal morphine exposure decreases susceptibility of adult male rat offspring to bicuculline seizures

The purpose of this study was to investigate the effect of prenatal exposure to morphine (5-10 mg/kg twice daily on days 11-18 of gestation) on bicuculline seizure susceptibility and to examine the interaction of prenatal morphine exposure and hormonal background in adult male rats. The data demonstrate that prenatal morphine exposure does not affect clonic but decreases susceptibility to tonic-clonic bicuculline seizures in intact male rats. Thus, the present data support our previous work demonstrating alterations in seizure susceptibility of adult morphine-exposed animals.

Prenatal methotrexate exposure delays onset of low Mg(2+)-induced epileptiform discharges in the entorhinal cortex

We determined the effects of prenatal exposure to DNA synthesis inhibitor methotrexate (MTX) on: (a) the susceptibility to low Mg(2+)-induced epileptiform activity in deep layers (IV-V) of medial entorhinal cortex in vitro; and (b) neuronal counts in this area. Low Mg(2+)-induced discharges developed significantly later in slices from prenatally MTX-exposed rats than in control slices. Neuronal counts were increased in the layer V of medial entorhinal cortex of prenatally MTX-exposed rats. Results indicate that: (a) MTX-induced prenatal brain DNA impairment is antiepileptogenic; and (b) simple increases in neuronal numbers may not be associated with epileptogenic effects.